Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units.

ABSTRACT:

Background

Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admit

SUBMITTER: Fang WF 

PROVIDER: S-EPMC5503229 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature